GlassScriptPhysician profile
Cathleen R Faris Guyol
NPI 1699770297
$562.68
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $94.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $143.97 | 2019-2020 | |
| Pfizer INC. | $90.09 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $80.13 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.21 | 2019-2020 | |
| Amgen INC. | $30.76 | 2019 | |
| Therapeuticsmd, INC. | $30.01 | 2019 | |
| Vertical Pharmaceuticals, LLC | $28.67 | 2019 | |
| Lupin INC. | $27.20 | 2019-2020 | |
| Duchesnay USA Incorporated | $26.13 | 2019 | |
| Boston Scientific Corporation | $18.81 | 2019 | |
| Exeltis, USA INC. | $18.26 | 2020 | |
| Merck Sharp & Dohme LLC | $17.75 | 2019 | |
| Glaxosmithkline, LLC. | $12.69 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathleen Faris Guyol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.